Gorsh, Boris

Single‐agent belantamab mafodotin in patients with relapsed/refractory multiple myeloma: Final analysis of the DREAMM‐2 trial

Nooka, A. K., Cohen, A. D., Lee, H. C., Badros, A., Suvannasankha, A., Callander, N., Abdallah, A., Trudel, S., Chari, A., Libby, E. N., et al. (2023) · Cancer

Multiple Myeloma Research and TreatmentsMonoclonal and Polyclonal Antibodies Research

Cited by 73

Treatment patterns and overall survival of patients with double-class and triple-class refractory multiple myeloma: a US electronic health record database study

Wang, P. F., Yee, C. W., Gorsh, B., Zichlin, M. L., Paka, P., Bhak, R. H., Boytsov, N., Khanal, A., Noman, A., DerSarkissian, M., et al. (2023) · Leukemia & Lymphoma

Multiple Myeloma Research and TreatmentsChronic Lymphocytic Leukemia Research

Cited by 35